Retsevmo ® ▼ (selpercatinib)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Retsevmo Summary of Product Characteristics (SmPC)

What are the the dosing considerations for Retsevmo® ▼ (selpercatinib)?

Selpercatinib may be taken with or without food unless coadministered with a proton pump inhibitor.

Detailed Information

  • The recommended dose of selpercatinib in adult and adolescent patients 12 years of age or older is 

    • 160 mg orally twice daily for patients with an actual body weight ≥50 kg, and

    • 120 mg orally twice daily for patients with an actual body weight <50 kg.1

  • Patients should take the doses at approximately the same time every day.1

  • If a patient vomits or misses a dose, the patient should be instructed to take the next dose at its scheduled time. An additional dose should not be taken.1

  • Selpercatinib capsules must be swallowed whole if possible. lf a patient cannot swallow the capsules, then alternative administration instructions must be followed to ensure the integrity of the selpercatinib dose.2

  • Selpercatinib may be taken with or without food unless coadministered with a PPI.1

  • Selpercatinib is taken orally twice daily until disease progression or unacceptable toxicity. Table 1 details the recommended dose of selpercatinib based on actual body weight.1

Table 1. Recommended Selpercatinib Dosage1,3

Patient Weighta

Recommended Dosage

<50 kg

120 mg orally twice daily

50 kg

160 mg orally twice daily

a Based on actual patient weight.

References

1. Retsevmo [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Retevmo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.

Glossary

PPI = proton pump inhibitor

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Date of Last Review: January 04, 2021


Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request